To place an order call
1-800-299-3431
|
|
 |
Our pioneering product portfolio includes ABLAVAR™(gadofosveset trisodium)—the first and only FDA approved blood pool contrast agent for magnetic resonance angiography (MRA), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), the world’s leading cardiac perfusion imaging agent and DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, the leading cardiac ultrasound contrast agent in the US.
For comprehensive information about our products, including full Prescribing Information, and support services, please select a product below:
 ABLAVAR™ (gadofosveset trisodium)
Ordering Information:
To place an order call
1-800-299-3431
|
Product Information:
Product Website
Material Safety Data Sheet (MSDS) (PDF)
Full Prescribing Information including boxed WARNING regarding Nephrogenic Systemic Fibrosis (NSF) (PDF)
INDICATIONS:
ABLAVAR™ is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
CONTRAINDICATIONS:
History of a prior allergic reaction to a gadolinium-based contrast agent.
IMPORTANT SAFETY INFORMATION:
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2), or
- acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
In these patients, avoid use of gadolinium-based contrast agents unless the
diagnostic information is essential and not available with non-contrast enhanced
magnetic resonance imaging (MRI). NSF may result in fatal or debilitating
systemic fibrosis affecting the skin, muscle, and internal organs. Screen all patients
for renal dysfunction by obtaining a history and/or laboratory tests. When
administering a gadolinium-based contrast agent, do not exceed the recommended
dose and allow a sufficient period of time for elimination of the agent from the body
prior to any re-administration.
|
ABLAVAR™ Injection: As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered. As with other paramagnetic contrast agents, caution should be exercised in patients with renal insufficiency due to the possibility of further deterioration in renal function.
In clinical trials, a small increase (2.8 msec) in the average change from baseline in QTc was observed at 45 minutes. These QTc prolongations were not associated with arrhythmias or symptoms. Caution should be used in patients at high risk for arrhythmias due to baseline QTc prolongation.
Have emergency resuscitative equipment available prior to and during ABLAVAR™ administration.
Please See Full Prescribing Information including boxed WARNING regarding Nephrogenic Systemic Fibrosis (NSF)
|
|
DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Ordering Information:
| Catalog Numbers |
| DE4 |
4-Vial Kit US |
| VMIX |
VIALMIX® |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com
|
Product Information:
Product Website
Material Safety Data Sheet (MSDS) (PDF)
Full Prescribing Information including boxed WARNING
regarding serious cardiopulmonary reactions (PDF)
Revised Healthcare Provider Letter (PDF)
DEFINITY® Return Policy
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.
- Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
- In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
- Always have resuscitation equipment and trained personnel readily available.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please See Full Prescribing Information and Letter to Healthcare Providers
|
|
VIALMIX®
Ordering Information:
| Catalog Numbers |
| VMIX |
VIALMIX®* |
| *A VIALMIX® is provided at no charge to customers who use DEFINITY® |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com |
Product Information:
VIALMIX® is the activation device used with DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
When properly used, it ensures consistent activation of DEFINITY® each and every time.
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.
- Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
- In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
- Always have resuscitation equipment and trained personnel readily available.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please See Full Prescribing Information and Letter to Healthcare Providers
|
|
INTELLPIN® (Dispensing Pin)
|
Ordering Information:
| Catalog Numbers |
| IPIN |
Box of 4 Intellipins® |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com |
Product Information:
A Simple And Efficient Alternative To Needles
For activated DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension only.
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
The safety and efficacy of DEFINITY® with exercise stress or pharmacologic stress testing have not been established.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred during or following perflutren-containing microsphere administration.
- Assess all patients for the presence of any condition that precludes DEFINITY® administration (see CONTRAINDICATIONS).
- In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after DEFINITY® administration (see WARNINGS).
- Always have resuscitation equipment and trained personnel readily available.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration (see ADVERSE REACTIONS). The risk for these reactions may be increased among patients with pulmonary hypertension or unstable cardiopulmonary conditions. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please See Full Prescribing Information and Letter to Healthcare Providers
|
|
Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)
Ordering Information:
| Catalog Numbers |
| CA2D |
2-Vial Kit |
| CAKD |
5-Vial Kit |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com |
Product Information:
Product Website
Material Safety Data Sheet (MSDS) (PDF)
Prescribing Information (PDF)
Important Safety Information:
Exercise and pharmacologic stress testing should be performed only
under the supervision of a qualified physician. Cardiolite® has been
rarely associated with acute severe allergic events of angioedema
and urticaria. The most frequently reported adverse events include
headache, chest pain/angina, ST segment changes on
ECG, nausea, and abnormal taste and smell. |
|
TechneLite® (Technetium Tc99m Generator) |
Neurolite® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) |
Thallium 201 (Thallous Chloride Tl201 Injection)
- Refer to the chart below to convert into mCi's.
- For each mCi needed at administration time, multiply by the factor shown in your time zone.
- Total your mCi's for all administrations and round to the nearest whole mCi.
- Call your Lantheus Medical Imaging Customer Service Representative and place your order in mCi (5 mCi minimum order).
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com
|
Product Information:
- Selection of sizes that remain the most extensive
- Efficient 2 mCi/ml concentration at label calibration
- Price per mCi ordering
- More precise ordering
- Record of on-time delivery nationwide
- Easy to order
- Easy to use
Prescribing Information (PDF)
Material Safety Data Sheet (MSDS) (PDF)
Important Safety Information:
Adverse patient reaction to Tl 201 is extremely rare. Rashes and/or temporary
low blood pressure have occurred, which have been treated with no further
reported complications. |
| |
EST |
CST |
MST |
PST |
| 02:00 AM |
0.945 |
0.954 |
0.963 |
0.972 |
| 03:00 AM |
0.954 |
0.963 |
0.972 |
0.981 |
| 04:00 AM |
0.963 |
0.972 |
0.981 |
0.991 |
| 05:00 AM |
0.972 |
0.981 |
0.991 |
1.000 |
| 06:00 AM |
0.981 |
0.991 |
1.000 |
1.010 |
| 07:00 AM |
0.991 |
1.000 |
1.010 |
1.019 |
| 08:00 AM |
1.000 |
1.010 |
1.019 |
1.029 |
| 09:00 AM |
1.010 |
1.019 |
1.029 |
1.039 |
| 10:00 AM |
1.019 |
1.029 |
1.039 |
1.049 |
| 11:00 AM |
1.029 |
1.039 |
1.049 |
1.059 |
| 12:00 PM |
1.039 |
1.049 |
1.059 |
1.069 |
| 01:00 PM |
1.049 |
1.059 |
1.069 |
1.079 |
| 02:00 PM |
1.059 |
1.069 |
1.079 |
1.089 |
| 03:00 PM |
1.069 |
1.079 |
1.089 |
1.100 |
| 04:00 PM |
1.079 |
1.089 |
1.100 |
1.110 |
| 05:00 PM |
1.089 |
1.100 |
1.110 |
1.121 |
| 06:00 PM |
1.100 |
1.110 |
1.121 |
1.132 |
| 07:00 PM |
1.110 |
1.121 |
1.132 |
1.142 |
| 08:00 PM |
1.121 |
1.132 |
1.142 |
1.153 |
|
|
Gallium 67 (Gallium Citrate Ga67 Injection)
Ordering Information:
| Catalog Numbers |
| GA6 |
6.6mCi |
| GA8 |
8.8mCi |
| GA12 |
13.2mCi |
| GA18 |
19.8mCi |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com |
Product Information:
The Greatest Choice of Vials Available for Flexible Ordering and Reduced Waste
- From the first company to offer Gallium Citrate Ga 67
- High purity for optimal image quality; at time of calibration:
- not less than 99.89% Ga 67
- less than 0.01% Ga 66
- less than 0.1% other radiocontaminants
- Unsurpassed record of on-time delivery nationwide
Prescribing Information (PDF)
Material Safety Data Sheet (MSDS) (PDF)
Important Safety Information:
Adverse reactions are rare and include allergic reactions, skin rash and nausea.
Convenience and Safety:
Widest selection of vial sizes to maximize number of usable doses and reduce waste
Pre-calibration delivery and seven-day post-calibration expiration provide ordering
flexibility to meet scheduling demands
2mCi/ml concentration at calibration allows easy injection pre- and post-calibration
Securitainer packaging and shield prevent spills, permit easy handling
and minimize radiation exposure |
|
Xenon 133 (Xenon Xe 133 Gas)
Ordering Information:
| Catalog Numbers |
| X110 = 1 x 10mCi Vial |
X120 = 1 x 20mCi Vial |
| X510 = 5 x 10mCi Vial |
X520 = 5 x 20mCi Vial |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com
|
Product Information:
- Used in millions of studies
- Provides functional information during first breath, equilibrium and wash-out phases
- Record of on-time delivery nationwide
Prescribing Information (PDF)
Material Safety Data Sheet (MSDS) (PDF)
Important Safety Information:
Adverse reactions related to the use of this agent have not been reported to date.
Convenience and Safety:
Single-dose dispensing system reduces radiation exposure
Shielded vial storage and transfer minimizes radiation exposure
Pre-calibration delivery and 10-day post-calibration expiration provide ordering flexibility to meet scheduling demands |
|
|
